Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DosEmi study of pharmacokinetic-guided emicizumab dosing in congenital haemophilia A
NL-OMON60257Phase 4Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by University Medical Center Utrecht. Started Sep 2022; status: recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON60257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60257.